Reuters logo
BRIEF-Ose Immunotherapeutics presents new data strengthening the rationale of myeloid checkpoint inhibitor OSE-172
October 2, 2017 / 4:37 PM / 20 days ago

BRIEF-Ose Immunotherapeutics presents new data strengthening the rationale of myeloid checkpoint inhibitor OSE-172

Oct 2 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:

* OSE IMMUNOTHERAPEUTICS PRESENTS NEW DATA STRENGTHENING THE RATIONALE OF MYELOID CHECKPOINT INHIBITOR OSE-172 AS AN IMMUNE CANCER TREATMENT

* “WE LOOK FORWARD TO BEGINNING CLINICAL TRIALS IN ONCOLOGY BY END OF 2018” - CEO

* COMPANY INTENDS TO ENTER CLINIC WITH OSE-172 IN ONCOLOGY BY END OF 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below